Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI versus tiotropium in COPD over 24 weeks
2012-003973-24Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of umeclidinium, vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Clinic visit trough FEV1 on Treatment Day 169. Started Dec 2012; status: completed.
02
Drugs
umeclidiniumvilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-003973-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003973-24.